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CARTILAGE BIOLOGY IN OSTEOARTHRITIS: ACTIVATION OF MATRIX
DEGRADING ENZYMES
C.B. Little1,2, M.T. Jackson1,2. 1Univ. of Sydney, St Leonards, Australia;
2Kolling Inst. of Med. Res., St Leonards, Australia
While osteoarthritis (OA) is a disease involving all joint tissues,
progressive cartilage erosion remains a pathognomonic feature and
a major indicator of the need for replacement surgery. Through
the use of genetically-modiﬁed mice, our understanding of the
molecular mechanisms that drive cartilage erosion in OA has greatly
improved. Factors regulating two particular pathways have emerged as
being critical in modulating OA cartilage pathology: (1) chondrocyte
differentiation/hypertrophy, and (2) proteolysis of key matrix proteins
(aggrecan and collagen) by metalloproteinases. These two pathways
may converge as chondrocyte hypertrophic differentiation is associated
with upregulation of a number of signiﬁcant matrix degrading enzymes
(ADAMTS and MMPs). However, data from MMP-13 KO mice may suggest
it is the MMP activity rather than chondrocyte hypertrophy per se, that
is the critical step in OA-cartilage degradation.
Despite localised pathology we found wide-spread upregulation of
chondrocyte MMP1, 2, 3, 13 and 14 mRNA in OA, suggesting local pro-
enzyme activation regulates focal cartilage breakdown. We identiﬁed the
serine proteinase, activated protein C (APC) but not its zymogen (PC), as
a potential regulator of MMP activation in cartilage. PC and the proteins
necessary for its activation (EPCR, TM) are expressed by chondrocytes,
and PC/APC is increased in areas of MMP activation in OA. In healthy
cartilage, an inﬂammatory stimulus (IL-1, TNF) is required for APC effect.
In contrast, APC alone induces aggrecan and collagen proteolysis by
MMPs in OA human cartilage. The effect of APC was still augmented by
IL-1 stimulation in OA cartilage, even where IL-1 itself had no signiﬁcant
effect on degradation. APC did not regulate expression of MMPs or TIMPs
but increased activation of pro-MMP2, 9 and 13 present in OA human
cartilage.
We found that APC cannot directly activate recombinant pro-MMP2, 9
or 13, and therefore investigated whether it was acting through PARs.
Chondrocyte PAR expression is increased in OA and by inﬂammatory
cytokines, and PARs are implicated in regulating MMP expression and
activation. We found no difference in vitro in basal or IL-1 stimulated
aggrecan or collagen proteolysis, MMP activity or mRNA expression in
PAR-1 or PAR-2 KO compared with wild type (WT) cartilage, suggesting
neither PAR alone is critical for cartilage degradation in mice. We
conﬁrmed this in vivo, observing no change in cartilage erosion compared
to WT in PAR-1 or -2 KO 8 weeks after DMM-induced OA, a time when
MMP-13 activity is critical for cartilage breakdown. In WT cartilage in
the presence of IL-1, APC induced aggrecan and collagen proteolysis,
and pro-MMP2, 9 and 13 activation. There was no diminution in
APC action in PAR-1 or -2 KO cartilage, indicating its effect was
not dependent on either receptor. Surprisingly, APC administration in
WT mice commencing 1 week after DMM surgery and continuing
twice weekly until sacriﬁce (week 8) signiﬁcantly reduced cartilage
degradation. This chondroprotection was not associated with altered
cartilage aggrecan loss nor the appearance of the MMP-cleaved aggrecan
neoepiope DIPEN. Initiating APC treatment 4 weeks after DMM surgery
failed to alter cartilage degradation. These in vivo results implicate the
effects of APC on other tissues in regulating OA cartilage pathology,
and suggest that early intervention, perhaps to modify acute joint
inﬂammation, may be required prevent long-term cartilage degradation
after joint injury.
Local activation of MMPs is a critical step in cartilage degradation in
OA, providing a potential therapeutic target. However, understanding
the interaction between all joint tissues, and the role of inﬂammation in
the initiation and progression of cartilage degradation in post-traumatic
OA requires further investigation.
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DEBATE: IS SUBCHONDRAL BONE OR ARTICULAR CARTILAGE THE
BEST TARGET FOR DMOAD DEVELOPMENT? BONE
D.M. Findlay. Univ. of Adelaide, Adelaide, Australia
Although the major disease of joints, osteoarthritis (OA), is characterised
by progressive degenerative damage to articular cartilage, ultimately it
is a disease of the whole joint. It is clearly important to identify the
cell(s) and tissue(s) that act as initiators of OA because decades of focus
on the articulate cartiage have failed to produce any efﬁcacious drugs
for OA or to prevent or slow the course of this disease. In this debate,
I will assert that it is the subchondral bone, which acts as both the
initiator and driver of OA and present some of the evidence supporting
a role for the subchondral bone in the aetiology and progression of OA.
Firstly, changes in bone shape can result in aberrant loading of joints
or impingement of cartilage, both of which constitute causal factors
for OA. Underlying these gross changes in bone shape are altered bone
micro-structure and changed gene and protein expression, which are
seen in the subchondral bone in OA and which probably occur skeleton
wide in this condition. Secondly, vascular pathology is likely to play a
role in the development of OA, as it does in a number of other skeletal
diseases. I will argue that this has a number of important consequences,
due to reduced subchondral blood ﬂow and ischemia in regions of the
subchondral bone: there is reduced diffusion of nutrients and oxygen
from the bone and marrow compartment to the articular cartilage and
there is death of osteocytes in the subchondral bone. The latter leads to a
cascade of events, which includes the initiation of osteoclastic resorption
of the non-vital bone, which can compromise the bony support for the
overlying cartilage. In addition, increased osteoclast activity in proximity
to the cartilage exposes chondrocytes to catabolic cytokines, such as
IL-1, leading to damage in the overlying articular cartilage. The possible
primary role of the subchondral bone in development of OA refocuses
attention on the bone compartment as a target for DMOADs.
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CHONDROCYTE HOMEOSTASIS
R. Loeser. Wake Forest Universtiy, Winston Salem, NC, USA
Chondrocytes in normal adult articular cartilage do not appear to be
very metabolically active. There is little to no cell proliferation and
matrix turnover appears to be quite low. The half-life of aggrecan has
been estimated to be in the range of 20 years while for type II collagen
it may be close to 100 years. Little is known about the turnover of
other matrix proteins but the expectation is that it would be low as
well. There is evidence that chondrocytes require a certain level of
mechanical stimulation to maintain homeostasis and when joint loading
stops, for example in a paralyzed limb, the cartilage progressively
thins. Because adult articular cartilage lacks a sufﬁcient progenitor
cell population, when chondrocytes die or become dysfunctional they
are not readily replaced with healthy cells. Aging contributes to the
development of osteoarthritis and aging changes affecting homeostasis,
including oxidative stress, are important. There is an age-related cell loss,
particularly in the superﬁcial zone of cartilage. As osteoarthritis develops,
there is evidence for a disruption in normal homeostasis which is made
worse by cell senescence. Besides age, the multiple factors that contribute
to the development of OA, such as joint injury, obesity, joint shape and
alignment, causes changes in the joint tissues that promote chondrocyte
“activation”. This activation is the result of increased activity in a complex
system of cell signaling pathways that results in an increase in synthesis
of cartilage matrix proteins (both normal and abnormal) as well as an
increase in production of inﬂammatory mediators and matrix degrading
enzymes. Matrix degradation generates fragments of matrix proteins
that promote further release of inﬂammatory mediators and matrix
degrading enzymes setting off a vicious cycle resulting in progressive
joint tissue destruction. Further research is needed in order to ﬁnd the
best targets for stopping or reversing this cycle before extensive damage
has occurred.
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PAIN PHYSIOLOGY IN OA
C.I. Svensson. Karolinska Inst.t, Stockholm, Sweden
OA is a common degenerative joint disease, characterized by damage
to articular cartilage, alterations of the underlying subchondral bone,
osteophyte formation and low-grade synovial inﬂammation. The most
prominent feature of OA is joint pain, however, the exact mechanism
of OA-associated pain is unclear and both peripheral and central
mechanisms has been suggested and mixed evidence of inﬂammatory
pain and neuropathic pain noted. Rheumatoid arthritis (RA) is also a
chronic joint disease with progressive cartilage and bone erosion. In
contrast to OA, RA is characterized with prominent joint inﬂammation,
pannus formation and systemic autoantibodies to proteins such as IgG,
type II collagen, citrullinated proteins or glucose-6-phosphate isomerase
